Clayton, Australia

Chrishan Samuel

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Cynata Therapeutics Limited. Active years: 2022.


% Patents Active = 100.0


 

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Chrishan Samuel

Introduction

Chrishan Samuel is a notable inventor based in Clayton, Australia. He has made significant strides in the field of medical technology, particularly in the treatment of allergic airway disease and asthma. His innovative approach utilizes advanced stem cell therapy to address these prevalent health issues.

Latest Patents

Chrishan Samuel holds a patent for a method aimed at treating allergic airway disease (AAD) and asthma. This invention involves the use of mesenchymoangioblast-derived mesenchymal stem cells (MSC-MSC) for therapeutic purposes. This groundbreaking method represents a promising advancement in the management of respiratory conditions.

Career Highlights

Samuel is currently associated with Cynata Therapeutics Limited, a company known for its pioneering work in stem cell technology. His role at the company allows him to contribute to the development of innovative treatments that can improve patient outcomes in respiratory health.

Collaborations

His work often involves collaboration with other professionals in the field. One of his notable coworkers is Simon Royce, with whom he shares insights and expertise to further enhance their research and development efforts.

Conclusion

Chrishan Samuel's contributions to the field of medical technology, particularly through his patent for treating allergic airway disease, highlight his innovative spirit and dedication to improving health outcomes. His work at Cynata Therapeutics Limited positions him as a key player in advancing stem cell therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…